Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Endometrial Neoplasms

• Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
• PRO1107 in Patients With Advanced Solid Tumors
• A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
• Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
• Pilot Window of Opportunity Trial (POET)
• Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
• Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma
• Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
• Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
• Iron Prehabilitation in Endometrial Cancer
• Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
• A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
• Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
• OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
• A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
• Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
• Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
• Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
• Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications
• Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
• Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
• A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer
• Hyperpolarized 13C MRI for Cancer Immunotherapy
• Study of ATR Kinase Inhibitor ART0380 as Monotherapy in Biologically Selected Advanced/Metastatic Solid Tumors Patients
• Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
• Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
• DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficie
• Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
• Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
• Study of Narazaciclib (ON 123300) Plus Letrozole in Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer
• Testing the Combination of APG-1252 and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
• A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
• A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors
• Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
• TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
• Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
• Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
• A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
• Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
• PRO1184 for Advanced Solid Tumors
• A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
• Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
• Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
• A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
• ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
• Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
• First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
• Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
• Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
• Oral AMXT 1501 Dicaprate in Combination With IV DFMO
• AMT-151 in Patients With Selected Advanced Solid Tumours
• Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
• Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
• 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
• Efficacy and Safety of TQB2450 Combined With Chemotherapy ± Anlotinib for Advanced Endometrial Cancer
• Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
• Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer
• Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
• Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
• A Study of XMT-1660 in Participants With Solid Tumors
• Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer
• Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
• GnRHa + Letrozole vs Diane-35 + Metformin in Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
• Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
• Niraparib in High-grade Endometrial Cancer Trial
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
• Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
• Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
• (VELA) Study of BLU-222 in Advanced Solid Tumors
• Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
• A Study of SGN-ALPV in Advanced Solid Tumors
• Endometrial Cancer Patientes MMR Deficient Comparing Chimiotherapy vs Dostarlimab in First Line
• A Study of SGN-B7H4V in Advanced Solid Tumors
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
• A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
• A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
• A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
• First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies
• A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma
• Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
• Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
• First in Human Study of TORL-1-23 in Participants With Advanced Cancer
• Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
• Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
• A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
• HMBD-001 in Advanced HER3 Positive Solid Tumours
• IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
• A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
• A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORC
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
• Advanced or Recurrent Ovarian, Cervical, and Endometrial Cancer Treated With SHetA2
• Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
• An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients
• Study of AK112 in the Treatment of Advanced Gynecological Tumors
• Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
• A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors
• 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
• Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
• Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer
• Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
• Radiation and TSR-042 in People With Endometrial Cancer After They Receive Surgery
• Study of Copanlisib and Ketogenic Diet
• Onapristone and Anastrozole in Refractory Estrogen and Progesterone Positive Endometrial Cancer
• Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
• A Study of SGN-STNV in Advanced Solid Tumors
• GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab
• Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
• Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer
• Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
• Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
• Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
• COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
• The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
• First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
• Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
• ZW25 in Women With Endometrial Cancers
• Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
• Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma
• Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation
• A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
• A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
• Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
• Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
• Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma
• Abemaciclib and Letrozole to Treat Endometrial Cancer
• Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
• Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
• A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
• Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
• Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.
• SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
• Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
• BP1001-A in Patients With Advanced or Recurrent Solid Tumors
• A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
• A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
• A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
• Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
• Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
• Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
• Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
• Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
• A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
• Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer
• Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
• Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
• A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
• TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
• Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
• Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
• Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
• FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
• A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
• Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma
• Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
• A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
• Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
• Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
• Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
• UTOLA: UTerin OLAparib
• Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer
• The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
• Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer
• Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
• COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in
• A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
• A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
• Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells
• Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
• Atezolizumab Trial in Endometrial Cancer - AtTEnd
• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
• Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
• Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
• Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer
• Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
• Effect of Fertility-sparing Therapy of Early Endometrial Cancer
• Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
• Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer
• ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
• Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
• Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
• CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
• Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.
• A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
• ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
• Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
• A Study to Assess the Efficacy and Safety of ABTL0812
• Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
• Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
• Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
• A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
• A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma
• Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
• Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
• Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer
• Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
• Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer
• A Study of Nivolumab in Selected Uterine Cancer Patients
• Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
• Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer
• Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
• Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
• PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
• SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
• VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
• Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
• An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
• A Study Evaluating MM-310 in Patients With Solid Tumors
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
• Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
• A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
• A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
• Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
• A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
• First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors
• A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
• A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
• Carboplatin-cyclophosphamide Combined With Atezolizumab
• Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
• Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
• Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
• Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
• A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium
• Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients
• A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
• Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
• Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
• Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
• A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
• Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
• A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
• Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
• Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
• Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
• Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
• A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
• MK-3475 Immunotherapy in Endometrial Carcinoma
• Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Canc
• Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
• Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium
• Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
• Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
• Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
• Pembro/Carbo/Taxol in Endometrial Cancer
• Biomarker Guided Treatment in Gynaecological Cancer
• Preoperative Olaparib Endometrial Carcinoma Study (POLEN)
• Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
• Survivorship Promotion In Reducing IGF-1 Trial
• Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
• Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
• Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
• Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
• Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
• A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer
• Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
• POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus
• Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
• Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
• A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
• Endometrial Cancer Biomarker Changes Following Exposure to Metformin
• Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
• Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
• Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion
• Exemestane in Advanced and Recurrent Endometrial Carcinoma
• Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
• Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery
• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
• A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer
• Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer
• Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
• The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
• Lymph Node Mapping in Patients With Endometrial Cancer
• A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
• Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
• Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
• PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
• [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
• Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
• An Endometrial Cancer Chemoprevention Study of Metformin
• Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
• Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
• Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer
• Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging
• Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
• Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease
• BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers
• Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
• Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
• Tachosil for the Prevention of Symptomatic Lymph Cysts
• Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer
• Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer
• Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
• A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
• A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
• A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
• GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer
• A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
• Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
• Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
• BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
• BKM120 as Second-line Therapy for Advanced Endometrial Cancer
• Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
• Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
• Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
• Study of FP-1039 in Subjects With Endometrial Cancers
• Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
• Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
• A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
• Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
• Trisenox® in Women With Metastatic Endometrial Cancer
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
• Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer
• Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
• Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
• AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
• Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
• Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
• Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
• Letrozole as a Treatment of Endometrial Cancer
• A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer
• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
• Sleep and Endometrial Cancer
• Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen
• The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
• Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
• Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
• Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer
• Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
• Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
• Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
• Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
• Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
• Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
• Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
• Endometrial Cancer - LOHP Alone and With 5FU
• CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
• A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
• Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
• Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors
• Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
• Regional Anesthesia and Endometrial Cancer Recurrence
• BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
• Papillary Serous Carcinoma of the Endometrium
• Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
• Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)
• Mifepristone for Patients With Endometrial Cancer and LGESS
• Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
• Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
• Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer
• Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery
• Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
• Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer
• Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
• END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin
• Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
• Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
• Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
• A Trial for Patients With Advanced/Recurrent Endometrial Cancer
• A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients
• Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
• Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
• A Study of Letrozole in the Treatment of Endometrial Cancer
• Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery
• Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
• Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
• Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer
• Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
• Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung
• Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
• Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
• Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
• Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)
• Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
• A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
• Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
• AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
• Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer
• EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
• Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
• RAD001 in Recurrent Endometrial Cancer Patients
• Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer
• Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
• Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
• Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
• Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
• Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
• Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
• Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
• Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
• Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer
• Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
• Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
• Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
• Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
• Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
• STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
• Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer
• Thalidomide in Treating Patients With Gynecologic Sarcomas
• Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
• Chemotherapy in Treating Patients With Sarcoma of the Uterus
• Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
• Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
• Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
• Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
• Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
• Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer
• Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
• Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
• Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
• Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
• Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
• Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
• Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
• Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
• Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer
• Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
• S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
• Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
• Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
• S9630, Medroxyprogesterone in Treating Women With Breast Cancer
• Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
• Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
• Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer
• High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma